Loading
A phase 1/2 trial of Sacituzumab govitecan in advanced solid tumours, run by Marengo Therapeutics, Inc., now recruiting.
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06827613 by Marengo Therapeutics, Inc., with 50 participants planned, started 2025-03-24 and due to reach its primary completion in 2027-01. Interventions recorded: STAR0602 and Sacituzumab Govitecan (SG).
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.